RA Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

RA Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$49.5M	Buy	20,992,669 +6,060,606	+41%	+$15.5M	0.52%	35
2025 Q4	$31.5M	Hold	14,932,063	–	–	0.32%	45
2025 Q3	$25.5M	Hold	14,932,063	–	–	0.31%	40
2025 Q2	$17.3M	Hold	14,932,063	–	–	0.29%	37
2025 Q1	$16.4M	Hold	14,932,063	–	–	0.27%	50
2024 Q4	$25.7M	Hold	14,932,063	–	–	0.34%	48
2024 Q3	$37M	Hold	14,932,063	–	–	0.43%	45
2024 Q2	$36.1M	Hold	14,932,063	–	–	0.48%	44
2024 Q1	$60.5M	Hold	14,932,063	–	–	0.77%	36
2023 Q4	$57.3M	Hold	14,932,063	–	–	0.9%	27
2023 Q3	$62M	Buy	14,932,063 +5,161,290	+53%	+$31.9M	1.22%	24
2023 Q2	$47M	Hold	9,770,773	–	–	0.89%	33
2023 Q1	$39.7M	Hold	9,770,773	–	–	0.9%	34
2022 Q4	$52.8M	Hold	9,770,773	–	–	1.07%	28
2022 Q3	$98M	Hold	9,770,773	–	–	2.09%	15
2022 Q2	$45.9M	Hold	9,770,773	–	–	1.22%	27
2022 Q1	$38.2M	Hold	9,770,773	–	–	0.83%	38
2021 Q4	$66M	Hold	9,770,773	–	–	1.16%	24
2021 Q3	$145M	Buy	+9,770,773	New	+$163M	2.01%	15

Other funds holding ABOS

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

RA Capital Management's ABOS Position: Q1 2026 in Review

RA Capital Management increased its Acumen Pharmaceuticals (ABOS) stake by 41% in Q1 2026, buying an estimated $15.5M and bringing the position to 20,992,669 shares worth $49.5M. The position accounts for 0.52% of the portfolio, ranked #35.

RA Capital Management first reported a position in ABOS in Q3 2021 and has held it in 19 quarters since. The position peaked at $145M in Q3 2021. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

RA Capital Management held 20,992,669 shares of Acumen Pharmaceuticals worth $49.5M as of Q1 2026.
RA Capital Management bought 6,060,606 Acumen Pharmaceuticals shares in Q1 2026, an estimated $15.5M.
Acumen Pharmaceuticals made up 0.52% of RA Capital Management's portfolio in Q1 2026, its #35 holding.
RA Capital Management first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
RA Capital Management's Acumen Pharmaceuticals position peaked at $145M in Q3 2021.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.